Here you can browse the complete list of projects on CDAS whose requests for data/biospecimens were approved.
Filter results of approved projects table below
| Name | Principal Investigator | Institution | Study | Date Approved | Project ID |
|---|---|---|---|---|---|
| Study of racial disparities in colorectal cancer screening using flexible sigmoidoscopy and cancer outcomes: An analysis of the PLCO Cancer screening trial. | Sejong Bae | UAB | PLCO | Oct 29, 2014 | PLCO-112 |
| Study of Small Aggressive Lung Cancers | Martin Tammemagi | Brock University / Henry Ford Health System | PLCO | Jul 1, 2006 | 2006-0245 |
| Subgroup Analysis of Primary NLST Mortality Endpoint | Grant Izmirlian | NCI | NLST | Feb 1, 2013 | NLST-10 |
| Subgroup Identification based on Lung Cancer Risk Prediction Model | Jon Steingrimsson | Brown University | NLST | Aug 5, 2020 | NLST-701 |
| Subset Analysis of Black Men Screened on the PLCO Prostate Cancer Screening Trial | Curtiland Deville | Johns Hopkins University | PLCO | Nov 2, 2015 | PLCO-172 |
| Subtype and grade classification using histopathologic slides | Gal Aviram | Curatio - DL | PLCO | Mar 2, 2022 | PLCOI-924 |
| Supporting NLST Investigator Use of Query Tool (QT) | Fred Prior | University of Arkansas for Medical Sciences | NLST | Nov 26, 2012 | NLST-3 |
| Surgical approach and outcomes in NLST patients with positive screening CT | Brendon Stiles | Weill Cornell Medicine | NLST | Feb 7, 2017 | NLST-281 |
| Surrogate endpoints for cancer screening trials | Adam Brentnall | Queen Mary University of London | NLST | Nov 5, 2024 | NLST-1345 |
| Surrogate endpoints for cancer screening trials | Adam Brentnall | Queen Mary University of London | PLCO | Nov 5, 2024 | PLCO-1719 |
| Surrogate endpoints for cancer screening trials | Adam Brentnall | Queen Mary University of London | PLCO | Dec 16, 2024 | PLCO-1769 |
| Surrogate endpoints for cancer screening trials | Adam Brentnall | Queen Mary University of London | HIPB | Nov 14, 2024 | HIPB-15 |
| Surrogate endpoints for cancer screening trials | Adam Brentnall | Queen Mary University of London | MEM | Nov 14, 2024 | MEM-7 |
| Surrogate endpoints for cancer screening trials | Adam Brentnall | Queen Mary University of London | MINN | Nov 14, 2024 | MINN-6 |
| Surrogate endpoints for cancer screening trials | Adam Brentnall | Queen Mary University of London | LSS | Nov 5, 2024 | LSS-9 |
| Surrogate endpoints for cancer screening trials | Adam Brentnall | Queen Mary University of London | JHLP | Nov 14, 2024 | JHLP-4 |
| Surrogate endpoints for cancer screening trials | Adam Brentnall | Queen Mary University of London | MAYO | Nov 14, 2024 | MAYO-5 |
| Survival Analysis and the Effect of Censoring for Lung Cancer | Azar Shahraz | AstraZeneca | PLCO | Jul 22, 2022 | PLCO-991 |
| Survival analysis in oncology clinical trial and its use in actuarial science | PatrĂcia Teplanová | Faculty of Economic Informatics, University of Economics in Bratislava | PLCO | Nov 13, 2023 | PLCO-1389 |
| Survival Analysis of Melanoma 2016 | Mohammad Tabatabai | Meharry Medical College | PLCO | May 1, 2019 | PLCO-477 |